title: A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
abstract: OBJECTIVE
  The purpose of this study was to examine the effects of of bromocriptin combined with clomiphene citrate in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
  
  
  METHODS
  Prospective, double-blind, controlled study.
  
  
  METHODS
  University teaching hospital.
  
  
  METHODS
  One hundred polycystic ovary patients and normal prolactin (PRL) who were clomiphene citrate resistant.
  
  
  METHODS
  Treatment group received 150 mg clomiphene citrate on days 5-9 and 7.5 mg bromocriptin continuously. Control group received the same protocol of clomiphene citrate combined with placebo.
  
  
  METHODS
  Hormonal status, follicular monitoring, ovulation rate.
  
  
  RESULTS
  Follicular development (follicular size greater than 15 mm) was observed in 12 (25.5%) and eight (15.1%) women in treatment and placebo group respectively ( P=0.29). The serum prolactin level was within normal limits in all patients before treatment. After 3 and 6 months of treatment with bromocriptin, there was a significant decrease in serum level of prolactin ( P=0.000001). No any significant differences was seen in ovulation, and serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone sulfate (DHEAS), progesterone (P) between treatment and placebo group after treatment.
  
  
  CONCLUSIONS
  The only significant effect of long-term bromocriptin therapy in clomiphene citrate resistant polycystic ovary women was to lower the serum prolactin concentration. It was also concluded that 10-15% of patients with polycystic ovaries experienced occasional ovulatory cycles and pregnancy whether or not they were on treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran. parsame@sums.ac.ir
authors.forename: Mohammad Ebrahim
authors.initials: ME
authors.lastname: Parsanezhad
authors.forename: Saeed
authors.initials: S
authors.lastname: Alborzi
authors.forename: Bahia
authors.initials: B
authors.lastname: Namavar Jahromi
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage*; D002996:Clomiphene / Q000008:administration & dosage; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D005299:Fertility Agents / Q000008:administration & dosage*; D006801:Humans; D010060:Ovulation / Q000187:drug effects*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011388:Prolactin / Q000097:blood*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D005299:Fertility Agents; D002996:Clomiphene; D001971:Bromocriptine; D011388:Prolactin